AI-designed lung drug shows early signs of slowing ageing
Insilico says early data from rentosertib, a drug candidate whose structure was developed with artificial intelligence, indicate it may reduce biological hallmarks of ageing. The medicine is being developed for a rare lung condition. The available RSS reports do not give trial size, study phase, safety findings or the strength of the ageing-related effect.
Why it matters
The findings offer an early test of whether AI-assisted drug discovery can produce clinically meaningful treatments.
Sources
finite. summarises the reporting above and links to each original. We do not reproduce full articles. Read the sources for complete coverage.
Part of the September 7, 2026 brief.